Skip to main content
The driveway to the Kay Jewelers Pavilion on our Akron Campus will be closed for 2-4 weeks beginning Oct. 10. Click HERE for details.
Go to homepage

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Description:

For complete information, please view the study at clinicaltrials.gov

Interested in participating?
We are currently recruiting
Study Sponsor:

Children's Oncology Group

Full IRB Study Title:
Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
IRB Study ID:
150914
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org

Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program